Skip to search formSkip to main contentSkip to account menu

OPC 21268

Known as: Acetamide, N-(3-(4-((4-(3,4-dihydro-2-oxo-1(2H)-quinolinyl)-1-piperidinyl)carbonyl)phenoxy)propyl)-, OPC-21268 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

PiperidinesQuinolonesVasopressin Antagonist

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Effects of hypertonic stimuli and arginine vasotocin (AVT) on water absorption response in Japanese treefrog, Hyla japonica.
2008
2008
Effects of arginine vasotocin and vasopressin receptor antagonists on Na+ and Cl- transport in the isolated skin of two frog species, Hyla japonica and Rana nigromaculata.
2005
2005
Preparation of highly potent and selective non-peptide antagonists of the arginine vasopressin V1A receptor by introduction of a 2-ethyl-1H-1-imidazolyl group.
To find a new series of arginine vasopressin (AVP) V1A receptor antagonists, the influence of the 2-phenyl group of 2-phenyl-4… 
1999
1999
Treatment of brain edema with a nonpeptide arginine vasopressin V1 receptor antagonist OPC-21268 in rats.
OBJECTIVE Recent experimental evidence suggests that centrally released arginine vasopressin plays a significant role in brain… 
1996
1996
Effect of a nonpeptide vasopressin V1 antagonist (OPC-21268) on experimental accelerated focal glomerulosclerosis.
The effects of the nonpeptide orally effective vasopressin V1 receptor antagonist OPC-21268 were studied in progressive focal… 
1994
1994
Vasopressin and a nonpeptide antidiuretic hormone receptor antagonist (OPC-31260).
The development of nonpeptide orally active AVP analogues has provided a new tool with which to assess the physiological and… 
1993
1993
Characterization of a novel non-peptide vasopressin V1 receptor antagonist (OPC-21268) in the rat.
A non-peptide, orally effective, vasopressin (AVP) V1 receptor antagonist 1-(1-[4-(3-acetylaminopropoxy) benzoyl]-4-piperidyl)-3… 
1993
1993
Pharmacokinetics, Safety, and Pharmacologic Effects of OPC‐21268, a Nonpeptide Orally Active Vasopressin V1 Receptor Antagonist, in Humans
The pharmacokinetics, safety, and pharmacologic effects of OPC‐21268, a nonpeptide orally active vasopressin V1 receptor… 
1993
1993
Distinct mechanisms of action of V1 antagonists OPC-21268 and [d(CH2)5Tyr(Me)AVP] in mesangial cells.
The effects of two arginine vasopressin (AVP) V1 receptor antagonists, a peptide analogue [d(CH2)5Tyr(Me)AVP] and an orally… 
1992
1992
Effects of a Nonpeptide Vasopressin Antagonist (OPC‐21268) on Cytosolic Ca2+ Concentration in Vascular and Cardiac Myocytes
A selective V, antagonist, l-{l-[4(3-acetylaminopropoxy)benzoyl]-4-piperidyl}-3,4-dihydro-2(1H)-quinolinone (OPC-21268), which is… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)